Sourasky Medical Center (Ichilov)
Pancreatic cancer treatment cost in Israel typically involves a diagnostic PET/CT scan ranging from $1,300 to $1,800 and primary pancreatic cancer surgery which runs $38,000 to $61,000. Total expenses depend on the tumor stage, chosen surgical approach, and hospital stay duration. Patients can expect 20-40% savings compared to the US. Top cities for this treatment include Tel Aviv, Jerusalem, and Haifa.
Typical Pancreatic Cancer Treatment Costs in Israel
Bookimed Expert Insight: Patients seeking high-volume surgical expertise should consider Sourasky Medical Center, which performs 34,000 surgeries annually. For complex cases, choosing a JCI-accredited facility like Assuta allows patients to select specific top-tier surgeons. Sourasky offers specialized diagnostic packages starting around $3,950. Those requiring multidisciplinary care benefit from Hadassah Medical Center, where Forbes-listed specialists lead the gastrointestinal cancer division.
| Izrael | Turcja | Austria | |
| Terapia protonowa | od $48,000 | od $70,000 | od $80,000 |
| Procedura Whipple’a | od $38,500 | od $23,000 | od $45,000 |
| Operacja raka trzustki | od $38,000 | od $9,000 | od $40,000 |
| Nano-nóż | od $18,500 | od $9,500 | od $25,000 |
| Gamma Knife | od $13,800 | od $6,300 | od $32,000 |
Dr Sharon Peles specjalizuje się w nowotworach układu pokarmowego. Szkoliła się w prestiżowym centrum onkologicznym Royal Marsden Cancer Center w Londynie.
Prof. Merimsky specjalizuje się w raku trzustki i posiada wieloletnie doświadczenie w onkologii zdobyte w Centrum Medycznym Sourasky.
Prof. Nadir Arber od ponad 30 lat koncentruje się wyłącznie na nowotworach układu pokarmowego. Kieruje Centrum Profilaktyki Raka w renomowanym izraelskim Centrum Medycznym Sourasky.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.